• metastatic/advanced RCC (mRCC) - 1st line (L1) 11
• mRCC - L1 - PDL1 negative 1
• mRCC - L1 - PDL1 positive 4

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab plus bevacizumab

• versus all
• vs VEGF(R) inhibitor
• vs sunitinib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mRCC - L1 - PDL1 negative;